Vosaroxin is an anti-cancer quinolone derivative that acts as a DNA intercalator and a topoisomerase II inhibitor, causing p53 independent tumor cell apoptosis. Vosaroxin stabilizes cleavage complexes formed by topoisomerase IIα and IIβ, which results in an accumulation of DNA double-strand breaks. Vosaroxin showed antineoplastic activity in multiple solid tumor and hematologic cancer cell lines and has been in clinical trials for AML.
Vosaroxin is an anti-cancer quinolone derivative that acts as a DNA intercalator and a topoisomerase II inhibitor.
Expert review of hematology, 9(6), 529-534 (2016-05-10)
The outcomes of patients with relapsed or refractory acute myeloid leukemia (AML) are dismal, and effective treatment options in this patient population are therefore desperately needed. Vosaroxin is a first-in-class anticancer quinolone derivative that has shown promising activity in patients
Vosaroxin is a first-in-class anticancer quinolone derivative that targets topoisomerase II and induces site-selective double-strand breaks in DNA, leading to tumor cell apoptosis. Vosaroxin has chemical and pharmacologic characteristics distinct from other topoisomerase II inhibitors due to its quinolone scaffold.
Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute myeloid leukemia (AML) in Phase I-III trials. Here, we examine vosaroxin's mechanism of action and pharmacology, and we review its use in AML to
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.